Sab biotherapeutics to present at the bio ceo & investor conference

Sioux falls, s.d., feb. 23, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq:  sabs ), (“sab” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced samuel j. reich, the company's chairman and ceo, will present an overview of the company at the bio ceo & investor conference on monday, february 26, 2024 at 3:15 pm est.
SABS Ratings Summary
SABS Quant Ranking